Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN

globenewswire.com
NVS Novartis is listed as a company influencing the future of personalized healthcare. The article highlights the growth of the personalized medicines market but does not offer specific sentiment or performance details for Novartis. ABT Abbott Molecular is mentioned as a company featured in the personalized medicines market report. The article discusses the overall market growth and trends, but provides no specific sentiment or performance analysis for Abbott. QGEN QIAGEN is mentioned as a company featured in the personalized medicines market report. The article discusses the overall market growth and trends, but provides no specific sentiment or performance analysis for QIAGEN.

Personalized Medicines - Global Strategic Business Report 2026: Capitalize on the $496.6B Market by 2032 | Competitive Intelligence on Roche, Novartis, Abbott Molecular and QIAGEN Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Personalized Medicines - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.

The global personalized medicines market, valued at US$202.2 billion in 2025, is projected to reach US$496.6 billion by 2032, expanding at a compound annual growth rate (CAGR) of 13.7%. Market growth is being supported by advances in genomic sequencing, biomarker-based profiling, pharmacogenomics, liquid biopsy, artificial intelligence (AI) and clinical decision-support technologies.

Personalized medicine is reshaping healthcare by enabling treatment and prevention strategies based on patients' genetic, epigenomic and clinical profiles. This approach can improve therapeutic efficacy, reduce adverse reactions and support earlier identification of disease risks. Its adoption is accelerating across oncology, rare and genetic diseases, neurology, cardiology and infectious diseases.

Technologies such as CRISPR-Cas9 gene editing, monoclonal antibodies and molecular diagnostics are enabling therapies that target specific disease mechanisms. AI and machine learning are also becoming increasingly important as healthcare organizations seek to analyze large genomic datasets, identify clinically relevant patterns, accelerate therapeutic target discovery and improve treatment selection.

Despite strong growth prospects, the personalized medicines market continues to face barriers, including the cost of genetic testing, integration challenges within existing healthcare systems, complex regulatory requirements and concerns surrounding patient privacy. Addressing data governance, reimbursement and clinical implementation will be essential to broader adoption. At the same time, regulatory support, growing demand for targeted treatments and the potential for long-term healthcare cost savings are strengthening the market outlook.

Personalized Medicines Market Segmentation

Key Personalized Medicines Market Insights

Report Scope and Strategic Value

The report provides independent market analysis, annual sales data and forecasts from 2025 through 2032. It examines the competitive environment, growth opportunities, market restraints and evolving demand across major offerings, technologies, applications and end-use categories.

Organizations can use the findings to assess emerging revenue opportunities, prioritize geographic expansion, evaluate competitive positioning and support product development or investment decisions. The analysis also addresses how market shares may evolve across regions and segments, which categories are expected to record the strongest growth, and which companies are positioned to influence the future of personalized healthcare.

Companies Featured in the Personalized Medicines Market Report

Domain Expert Insights and Report Differentiators

Report Features

With personalized healthcare moving closer to mainstream clinical practice, the market is positioned for sustained expansion through 2032. Continued innovation in genomics, targeted therapeutics, AI-enabled analytics and clinical interpretation platforms is expected to improve diagnostic precision, treatment selection and patient outcomes while creating new opportunities across the global healthcare ecosystem.

Key Attributes

For more information about this report visit https://www.researchandmarkets.com/r/33bjq6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.